BLFE — Biolife Sciences Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro Cap

Annual cashflow statement for Biolife Sciences, fiscal year end - November 30th, USD millions except per share, conversion factor applied.

	2010 November 30th	2011 November 30th	2012 November 30th	2020 November 30th	2021 November 30th
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	10-K	PROSPECTUS	PROSPECTUS
Standards:	USG	USG	USG	U USG	U USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	1.72	-0.293	-0.202	-1.27	-0.457
Amortisation
Non-Cash Items	0.041	0.227	0.153	0.004	0.162
Unusual Items
Other Non-Cash Items
Changes in Working Capital	0	0.013	0.013	0.263	0.188
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Payable / Accrued Expenses
Net Change in Other Assets & Liabilities
Cash from Operating Activities	1.76	-0.04	-0.037	-1	-0.107
Capital Expenditures	—	—	—	-0.001	0
Purchase of Fixed Assets
Other Investing Cash Flow Items	-0.545	0	0	—	—
Acquisition of Business
Other Investing Cash Flow
Cash from Investing Activities	-0.545	0	0	-0.001	0
Financing Cash Flow Items	-1.53	0.037	0.034	—	—
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-1.22	0.038	0.034	0.989	0.075
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	0.004	-0.002	-0.003	0.035	-0.018